Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;81(1):19-30.
doi: 10.18999/nagjms.81.1.19.

＜Editors' Choice＞ Pulmonary Hypertension: Diagnosis, Management, and Treatment

Takahisa Kondo  1 , Naoki Okumura  1 , Shiro Adachi  1 , Toyoaki Murohara  2
Affiliations
Review

＜Editors' Choice＞ Pulmonary Hypertension: Diagnosis, Management, and Treatment

Takahisa Kondo et al. Nagoya J Med Sci. 2019 Feb.

Abstract

Pulmonary hypertension (PH) is a hemodynamic state that is characterized by a resting mean pulmonary artery pressure ≧ 25 mmHg. The common forms of PH are pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), PH caused by left-heart disease, and PH due to lung disease. Previously regarded as untreatable, the treatment of PAH has dramatically advanced since the introduction of the drug epoprostenol in 1999, with three-year survival rates improving from 30%-40% to over 85%. Drugs available for the specific treatment of PAH include endothelin-receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogs, and prostacyclin-receptor agonists. In the past decade, management and treatment of CTEPH have also improved. While pulmonary endarterectomy used to be the only option for the treatment of CTEPH, newer treatments include a soluble guanylate cyclase stimulator, which has proven to be an efficacious targeted therapy. Other cases benefit from balloon pulmonary angioplasty.

Keywords: Pulmonary hypertension; chronic thromboembolic pulmonary hypertension (CTEPH); pulmonary arterial hypertension; pulmonary hypertension (PAH).

PubMed Disclaimer

Conflict of interest statement

Takahisa Kondo, Naoki Okumura, and Shiro Adachi belong to departments endowed by Actelion Pharmaceuticals Japan, which is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Figures

Fig. 1
Fig. 1. Diagnostic algorithm for pulmonary arterial hypertension
Differential diagnosis of pulmonary arterial hypertension based on mean pulmonary arterial pressure, pulmonary arterial wedge pressure (PAWP), and pulmonary vascular resistance (PVR). CTEPH: chronic thromboembolic pulmonary hypertension. WU, Wood units
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41. - PubMed
    1. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–301. - PubMed
    1. Galie N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010;31(17):2080–2086. - PMC - PubMed
    1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. - PubMed
    1. Tamura Y, Kumamaru H, Satoh T, et al. Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension. Circ J. 2017;82(1):275–282. - PubMed

MeSH terms

Substances